Antigen News and Research

RSS

Study shows aging affects adaptive immune responses

Today at the 45th Annual Meeting & Exhibition of the American Association for Dental Research, researcher Jeffrey Ebersole, University of Kentucky, Lexington, USA, will present a study titled "Systemic Antibody Responses to Oral Bacteria with Aging." The AADR Annual Meeting is being held in conjunction with the 40th Annual Meeting of the Canadian Association for Dental Research.

21 Mar 2016

Newly developed computer models can simulate stem cell transplant recovery

Scientists at Virginia Commonwealth University have developed computer models that can simulate the recovery of the immune system in patients undergoing stem cell transplants.

18 Mar 2016

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

Janssen-Cilag International NV today announced that data from a post-hoc analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA (abiraterone acetate) plus prednisone provided an 11.8 months overall survival (OS) benefit (53.6 months vs 41.8 months; HR = 0.61 [95% CI, 0.43-0.87]; p = 0.0055), compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

15 Mar 2016

VolitionRx's NuQ blood test accurately detects 86% of subjects with Idiopathic Pulmonary Fibrosis

VolitionRx Limited today announced preliminary data from a pilot study demonstrating that the Company’s NuQ® blood test detected 86% of subjects with a deadly lung disease, called Idiopathic Pulmonary Fibrosis (IPF).

10 Mar 2016

CWRU researcher to customize tobacco mosaic virus to treat human cancers

A Case Western Reserve University researcher has been awarded more than $3 million in federal and foundation grants to turn common plant viruses into cancer sleuths and search-and-destroy emissaries.

10 Mar 2016

Real-world data confirm TDF efficacy for HBV

Treatment with tenofovir disoproxil fumarate elicits sustained virological responses and exhibits a favourable safety profile in a diverse population of patients with chronic hepatitis B virus infection, shows a French routine clinical practice study.

10 Mar 2016

Resistance to prior antiviral agents impacts TDF response

Taiwanese researchers find that virological response to tenofovir disoproxil fumarate in treatment-experienced patients with chronic hepatitis B virus infection can vary depending on the nucleos(t)ide analogue the patient is resistant to.

10 Mar 2016

Regulatory immune cells compromised in PAH

Research suggests that regulatory T cells may play a part in all subtypes of pulmonary arterial hypertension.

10 Mar 2016

Vitamin D deficiency during pregnancy linked to MS risk

Children born to mothers deficient in vitamin D during early pregnancy have an increased risk of developing multiple sclerosis as adults, researchers report.

8 Mar 2016

Research could change the way people look at gene expression, immune response

Research from the Single-Cell Genomics Centre on the Wellcome Genome Campus could change the way we look at gene expression and immune response. Published in Nature Methods, the new method, TraCeR, provides a powerful tool for research into immune response, vaccination, cancer and autoimmunity.

8 Mar 2016

ACGT awards new research grants to take researchers to next level in cancer treatment

Alliance for Cancer Gene Therapy, the nation's only nonprofit dedicated exclusively to cell and gene therapies for cancer, is delighted to announce the recipients of its 2016 ACGT Young Investigator Grants.

8 Mar 2016

Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

A study of obesity and related metabolic changes on bladder cancer incidence and deaths, and a plan to use stem cells to grow novel urinary tubes are among 10 research projects awarded funding by the Johns Hopkins Greenberg Bladder Cancer Institute.

7 Mar 2016

Means to target all tumor cells with one treatment uncovered

Research sponsored by Cancer Research UK has identified mutations common to all tumour cells. Immunotherapies specific for these mutations could deliver chemotherapeutic agents to all tumour cells and destroy them.

4 Mar 2016

Rice university researchers uncover elusive lung cancer cells

Researchers at Rice University and the University of Texas MD Anderson Cancer Center have uncovered a trick used by lung cancer cells to hide from the body's immune system.

3 Mar 2016

U-M researchers develop novel mouse model of children's brain cancer

Children with brain cancer may soon get some help from mice with the same disease, thanks to new research from University of Michigan Medical School scientists and their colleagues.

3 Mar 2016

WRAIR researchers publish results from Plasmodium vivax malaria vaccine study

Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.

27 Feb 2016

Aggregated forms of transthyretin can trigger JIA development

Juvenile idiopathic arthritis (JIA) is a the most common form of arthritis in children and affects approximately 50,000 individuals in the United States alone. Previous research suggested that autoimmune responses cause JIA, but the specific antigens that are responsible for driving autoimmunity have not been identified.

26 Feb 2016

Gene expression analysis points metastatic CRC patient to successful irbesartan therapy

A patient with recurrent metastatic colorectal cancer has been successfully treated with the angiotensin receptor blocker irbesartan, researchers report.

24 Feb 2016

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Asterias Biotherapeutics, Inc. today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML).

24 Feb 2016

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies.

24 Feb 2016